Sertraline (Zoloft)
What studies of Sertraline (Zoloft) found
At a glance, by condition
ME/CFS: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 6 findings, all C.
6 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Sertraline (Zoloft) might help some people with ME/CFS, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Sertraline (Zoloft) · ME/CFS is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Cognition (brain fog)1 study · 34 people took Sertraline (Zoloft) Uncertain –
Why this grade: Uncertain, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); helped less than vortioxetine, an active treatment; not a sign of harm.
Compared with another group, not randomised140 in the study · over 8 weeks · 50-200 mg/d
Cognition (brain fog) improved less than with the comparison treatment.
Sertraline (Zoloft) helped cognition (brain fog) less than vortioxetine in the one comparison. Uncertain · very low certainty –
- Serious risk of bias (ROBINS-I)
- Helped less than vortioxetine, an active treatment; not a sign of harm
See the 1 study
-
- People in the study
- 140 in the study
- Dose
- 50-200 mg/d
- Outcome
- Digital Symbol Substitution Test (DSST) Digital Symbol Substitution Test
- Effect
- worse
- Risk of bias
ROBINS-I: Serious
- Confounding
- NI. adjustment for confounding isn't reported
- Selection of participants
- NI. how the comparison group was chosen isn't reported
- Classification of interventions
- Low. assigned and recorded at the start
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- NI. missing data aren't reported
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- Moderate. a pre-specified primary outcome
Depression1 study · 34 people took Sertraline (Zoloft) Uncertain –
Why this grade: Uncertain, very low certainty, from controlled studies: serious risk of bias (ROBINS-I); helped less than vortioxetine, an active treatment; not a sign of harm.
Compared with another group, not randomised140 in the study · over 8 weeks · 50-200 mg/d
Depression improved less than with the comparison treatment.
Sertraline (Zoloft) helped depression less than vortioxetine in the one comparison. Uncertain · very low certainty –
- Serious risk of bias (ROBINS-I)
- Helped less than vortioxetine, an active treatment; not a sign of harm
See the 1 study
-
- People in the study
- 140 in the study
- Dose
- 50-200 mg/d
- Outcome
- Montgomery-Asberg Depression Rating Scale (MADRS) Montgomery-Asberg Depression Rating Scale
- Effect
- worse
- Risk of bias
ROBINS-I: Serious
- Confounding
- NI. adjustment for confounding isn't reported
- Selection of participants
- NI. how the comparison group was chosen isn't reported
- Classification of interventions
- Low. assigned and recorded at the start
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- NI. missing data aren't reported
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- Moderate. a pre-specified secondary outcome
ME/CFS
Symptoms
Autonomic symptoms1 study · 79 people took Sertraline (Zoloft) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.
Studies with no comparison group79 in the study · 6-month period · 50-mg, daily
Autonomic symptoms improved.
The evidence is very uncertain about the effect of sertraline (Zoloft) on autonomic symptoms in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Not all results were tested against chance
See the 1 study
-
A Pilot Study of Sertraline for the Treatment of Chronic Fatigue Syndrome (1994)
- People in the study
- 79 in the study
- Dose
- 50-mg, daily
- Outcome
- Palpitations
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Depression1 study · 79 people took Sertraline (Zoloft) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.
Studies with no comparison group79 in the study · 6-month period · 50-mg, daily
Depression improved.
The evidence is very uncertain about the effect of sertraline (Zoloft) on depression in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Not all results were tested against chance
See the 1 study
-
A Pilot Study of Sertraline for the Treatment of Chronic Fatigue Syndrome (1994)
- People in the study
- 79 in the study
- Dose
- 50-mg, daily
- Outcome
- Depression
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 79 people took Sertraline (Zoloft) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.
Studies with no comparison group79 in the study · 6-month period · 50-mg, daily
Fatigue improved.
The evidence is very uncertain about the effect of sertraline (Zoloft) on fatigue in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Not all results were tested against chance
See the 1 study
-
A Pilot Study of Sertraline for the Treatment of Chronic Fatigue Syndrome (1994)
- People in the study
- 79 in the study
- Dose
- 50-mg, daily
- Outcome
- Fatigue
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Pain1 study · 79 people took Sertraline (Zoloft) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.
Studies with no comparison group79 in the study · 6-month period · 50-mg, daily
Pain improved.
The evidence is very uncertain about the effect of sertraline (Zoloft) on pain in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Not all results were tested against chance
See the 1 study
-
A Pilot Study of Sertraline for the Treatment of Chronic Fatigue Syndrome (1994)
- People in the study
- 79 in the study
- Dose
- 50-mg, daily
- Outcome
- Myalgia
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Sleep1 study · 79 people took Sertraline (Zoloft) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.
Studies with no comparison group79 in the study · 6-month period · 50-mg, daily
Sleep improved.
The evidence is very uncertain about the effect of sertraline (Zoloft) on sleep in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Not all results were tested against chance
See the 1 study
-
A Pilot Study of Sertraline for the Treatment of Chronic Fatigue Syndrome (1994)
- People in the study
- 79 in the study
- Dose
- 50-mg, daily
- Outcome
- Sleep Disturbance
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Overall symptoms1 study · 79 people took Sertraline (Zoloft) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); not all results were tested against chance.
Studies with no comparison group79 in the study · 6-month period · 50-mg, daily
Overall symptoms improved.
The evidence is very uncertain about the effect of sertraline (Zoloft) on overall symptoms in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Not all results were tested against chance
See the 1 study
-
A Pilot Study of Sertraline for the Treatment of Chronic Fatigue Syndrome (1994)
- People in the study
- 79 in the study
- Dose
- 50-mg, daily
- Outcome
- abatement of symptoms
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Side effects
Side effects studies reported2 kinds
| Side effect | Studies that reported it |
|---|---|
| Nausea or stomach upset | 1 study |
| Trouble sleeping | 1 study |
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
12.5 to 50 mg at the start
- 2Raise
Raised step by step in 2 of 2 studies
- 3Top dose
Most often 50 mg (1 of 2 studies)
Doses across 2 studies
12.5 to 200 mg.
Each study’s dose, as printed
- 50 mg/day initially, reduced to 25 mg/day at Session 7 and 12.5 mg/day at Session 10, then discontinued, continued initially; tapered at the patient’s request Resolution of Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome symptoms following kanshoho, a low-pressure muscle relaxation technique: A case report. (2026)
- 50-200 mg/d Vortioxetine for Cognitive Impairment in Major Depressive Disorder During Post-COVID Syndrome: Real-World Evidence. (2025)
All papers
- Vortioxetine for Cognitive Impairment in Major Depressive Disorder During Post-COVID Syndrome: Real-World Evidence.2025 · compared with another group · 140 in the study
Summary
This prospective, open-label comparative study was carried out at 1 clinical site in people with post-COVID syndrome and new-onset major depressive disorder. A total of 140 participants were assigned to receive vortioxetine (n = 70), escitalopram (n = 36), or sertraline (n = 34) over 8 weeks. Vortioxetine was given at 10-20 mg/d, escitalopram at 10-20 mg/d, and sertraline at 50-200 mg/d. The primary outcome was change from baseline to end point in the Digital Symbol Substitution Test (DSST); secondary outcomes were change in the Montgomery-Asberg Depression Rating Scale (MADRS) and the Patient Reported Outcome Measurement Information System Fatigue Short Form 7a (PROMIS 7a). For DSST, participants assigned to vortioxetine showed significant changes from baseline to end point compared with escitalopram (least squares [LS] mean difference 8.25; 95% CI 6.25-10.25; P < .001) and sertraline (LS mean difference 8.00; 95% CI 5.95-10.06; P < .001). For total MADRS, the vortioxetine group showed significantly greater changes than escitalopram (LS mean difference -4.06; 95% CI -4.92 to -3.20; P < .001) and sertraline (LS mean difference -3.94; 95% CI -4.83 to -3.06; P < .001). Side effects, withdrawals, worsening, and the number analysed were not reported in the abstract. The authors state that vortioxetine has a significant procognitive effect and that antidepressant effects and improvement in fatigue symptoms (PROMIS 7a) also were observed. No limitations are stated in the abstract.
- SSRI Use During Acute COVID-19 Infection Associated with Lower Risk of Long COVID Among Patients with Depression2024 · compared with another group · 506,903 with outcome data · preprint
- SSRI use during acute COVID-19 and risk of long COVID among patients with depression.2024 · compared with another group · 302,626 with outcome data
Summary
This retrospective cohort used N3C electronic health records from patients with a depressive disorder and acute SARS-CoV-2 infection. The text reports 302,626 patients; 100,803 (33%) were SSRI users and 201,823 (67%) were nonusers. Table 1 lists 101,016 SSRI users and 202,354 nonusers. SSRI use was defined as beginning at least 30 days before COVID-19 and continuing through acute COVID-19. SSRI users were compared with all other patients, defined as nonusers. The outcome was Long COVID (PASC) diagnosis by ICD code U09.9 between 1 and 12 months (day 31 to 365) after acute infection. SSRI users had a lower risk of Long COVID than nonusers (adjusted risk ratio 0.922, 95% CI 0.863 to 0.986). The unadjusted association was 1.042 (95% CI 0.984 to 1.104). New SSRI users also had a lower risk (adjusted risk ratio 0.886, 95% CI 0.780 to 0.985). For fluoxetine, sertraline, escitalopram, paroxetine, and citalopram, the study did not detect an association with Long COVID. No dose-response was found for fluoxetine 60 mg vs 10 mg (adjusted risk ratio 1.421, 95% CI 0.656 to 3.080). Harms, withdrawals, and people who worsened were not reported. The authors state limitations include binary time-invariant exposure, possible outcome misclassification, residual bias from observational design, and limited generalizability.
- A Pilot Study of Sertraline for the Treatment of Chronic Fatigue Syndrome1994 · no comparison group · 79 in the study
- Resolution of Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome symptoms following kanshoho, a low-pressure muscle relaxation technique: A case report.2026 · case report · 1 in the study
Summary
This case report described one 41-year-old woman with Long COVID who met diagnostic criteria for ME/CFS and presented to a psychosomatic medicine outpatient clinic. Kanshoho, a low-pressure muscle relaxation technique applied at approximately 5.0 N, was given as the primary intervention in 10 sessions over approximately 2.5 months, with brief advice on activity pacing. Sertraline at 50 mg/day was continued initially and later tapered to 25 mg/day at Session 7 and 12.5 mg/day at Session 10, then discontinued. There was no comparison group. Fatigue visual analog scale score changed from 79 mm to 0 mm, performance status from 7 to 0, and POMS-2 Total Mood Disturbance raw score from 136 to 19. At the tenth session, all symptoms—including generalized fatigue, PEM, pain, numbness, brain fog, and insomnia—had completely resolved. At a telephone follow-up 6 months after Session 10, the patient reported no symptom recurrence. New tightness in the lateral neck region was reported at the ninth session, and the authors reported no clear symptom deterioration during sertraline taper and discontinuation. The authors stated that causality cannot be inferred from a single case.
- Depression and brain fog as long-COVID mental health consequences: Difficult, complex and partially successful treatment of a 72-year-old patient-A case report.2023 · case report · 1 in the study
Summary
This case report describes one 72-year-old female with long COVID after COVID-19 infection, treated in a neurological day hospital and a psychiatric inpatient unit and followed as an outpatient. There was no comparison group. Between June 17 and July 8 2022 she was treated in a neurological day hospital without improvement in her health status. She then received outpatient psychiatric help and antidepressant therapy with sertraline 50 mg per day and mirtazapine 15 mg per day for almost 2 months, without significant improvement in her condition. In the psychiatric inpatient unit, between August 29 and September 23, 2022, she received venlafaxine up to 75 mg per day, trazodone up to 50 mg in the evening, nutritional supplements, enteral feeding, and non-drug therapy (visual art, music, drama, dance and movement therapy, occupational therapy, psychotherapy, physiotherapy). At hospitalization, PHQ-9 was 21 and CGI-S was 6; at discharge PHQ-9 was 8, CGI-S 3, and CGI-I 2. At the last outpatient follow-up visit on 01/5/2023, PHQ-9 was 5, CGI-S 3, and CGI-I 2. Mood, energy, anxiety, and sleep improved, but rapid fatigability, difficulty concentrating, unclear thinking, forgetfulness, and brain fog persisted; weight remained 48 kg with no weight gain, and she remained unable to resume work. Side effects and withdrawals were not reported.
- Bupropion augmentation in the treatment of chronic fatigue syndrome with coexistent major depression episode.2006 · case report · 1 in the study
Summary
This case report described one 39-year-old woman with chronic fatigue syndrome and a coexistent major depression episode, admitted to a psychiatric setting. She was given paroxetine 20 mg/day increased to 40 mg/day, and bupropion was added and gradually increased to 450 mg/day; treatment reached full remission after 6 weeks. There was no comparison group. Symptoms, BDI, MADRS and HAM-D were assessed. After 3 weeks, symptoms improved markedly, reaching full remission after 6 weeks; BDI was 22 at baseline and 5 after 6 weeks, MADRS was 25 and 6, and HAM-D was 22 and 6. On follow-up 6 and 12 months later, symptoms were still absent and she could enter a part time job. After an initial boost of energy, she deteriorated slightly. The authors stated that the report is a case and that controlled studies in larger CFS samples are warranted.
- Treatment of chronic fatigue syndrome with venlafaxine.1996 · case report · 2 in the study
- Non-Invasive Brain Stimulation for Post-COVID-19 Conditions: A Systematic Review.2025 · systematic review
Summary
This systematic review asked whether non-invasive or minimally invasive brain stimulation reduces symptoms of post-COVID-19 condition. Four databases were searched through April 2nd, 2024; 19 studies were included, covering tDCS, TMS, tVNS and toACS. Across the included studies, Klirová et al. (33 patients) found no significant intergroup difference in post-COVID-19 symptoms. Santana et al. (70 patients) reported a significant reduction in fatigue and anxiety and an improvement in quality of life with active HD-tDCS compared with sham. Oliver-Mas et al. (47 patients) reported a significant improvement of physical fatigue and depressive symptoms in the active tDCS group compared with sham. Gracia et al. (15 patients) found no significant improvement across groups. Vestito et al. (7 patients) reported a significant improvement of hyposmia comparing tDCS with sham. Sakib et al. (4 patients) detected no significant group differences for rTMS. Badran et al. (13 patients) reported a trend towards mild to moderate effects of tVNS on fatigue. Reported harms included transient burning or tingling during tDCS, mild and transient headache and dizziness, transient tingling on the scalp, transient mild skin irritation with tVNS, and transient pain at the TMS stimulation site. The authors state that sample sizes are small, many studies are case reports, randomization and control groups are often missing, and diagnostic criteria differ.
- Pharmacological treatment of chronic fatigue syndrome: focusing on the role of antidepressants.2009 · review
Summary
This review did not run its own trial; it summarized published data on pharmacological treatment of chronic fatigue syndrome (CFS), identified through a PubMed literature search. The review covers antidepressants and other psychotropic agents in CFS. In included randomized, placebo-controlled trials, moclobemide vs. placebo (47 vs. 43) showed clinically global improvement 51 vs. 33% (OR = 2.16); KPI mean difference between two groups was 0.28 favoring MCB, and Vigor subscale on POMS mean difference was 0.51 favoring MCB. Overall response by subjective global impression was 51% with moclobemide vs. 23% with placebo. At 12 weeks, MIR failed to separate from PBO on FS; at 24 weeks, CBT + MIR showed significantly more reduction in FS scores than PBO + CBT, with an observed difference of 5.5 (95% CI = 15.4 – 22), whereas MIR + CBT failed to separate from PBO + CBT. Fluoxetine failed to separate from PBO on SFS and BDI scores, and failed to demonstrate benefit on listed outcome measures. The review lists harms: TCAs potentially induce sedation and orthostatic hypotension; MAOIs have hypertensive crisis; stimulant medications carry risks of misuse, abuse, withdrawal, and diversion. Authors state research does not support definitive conclusions about antidepressant efficacy in CFS.
- Chronic fatigue syndrome in the psychiatric practice.2002 · review
Summary
This REVIEW ARTICLE concerns chronic fatigue syndrome (CFS) and reviews treatments for CFS, reporting cited trials rather than a new study. Vercoulen contrasted fluoxetine with placebo in 96 patients and did not find any significant effect on fatigue complaints or depression complaints. Wearden examined fluoxetine, placebo and physical exercise in 136 patients; fluoxetine gave a significant improvement of depression scores but a non-significant improvement of fatigue complaints, while physical exercise appeared to result in a significant improvement of fatigue complaints. Natelson studied phenelzine against placebo in 24 patients and found an improvement of fatigue complaints compared with placebo. Behan found a superior antidepressant effect of sertraline vs clomipramine in 40 patients, with no placebo group. Deale reported at final follow-up that 70% of the CBT group achieved a substantial improvement in physical functioning, compared with 19% of the relaxation group. Reference 38 found the number of patients showing clinical improvement was not significantly higher with hydrocortisone than with placebo; reference 39 showed a significant reduction in self-reported fatigue scores with hydrocortisone compared with placebo. Higher doses of cortisone in one study caused adrenal suppression in 40% of patients participating in active treatment. The authors conclude that antidepressants do not seem to have a positive influence on fatigue but appear beneficial for depression and social functioning; CBT and graded exercise show significant improvement and are the only treatments available for CFS patients; glucocorticoid therapy is not recommendable as a standard treatment. Limitations are not reported.
- Chronic fatigue syndrome.2000 · review
Summary
Clinical review searched January 1999 for randomised controlled trials of treatments for chronic fatigue syndrome. It assessed antidepressants, corticosteroids, exercise, prolonged rest, dietary supplements, immunotherapy, cognitive behavioural therapy, and oral nicotinamide adenine dinucleotide. In antidepressants, one RCT compared fluoxetine with placebo in 96 people and found no significant benefit; another allocated 136 people to exercise plus fluoxetine, exercise plus placebo, appointments plus fluoxetine, or appointments plus placebo and found no significant difference in fatigue. In corticosteroids, a trial in 32 people found nine people (28%) taking hydrocortisone improved compared with three (9%) taking placebo; a 65-person hydrocortisone trial found greater improvement on a self-rated wellness scale but other self-rating scales did not show significant benefit. In exercise, an RCT in 66 people reported 55% of the aerobic exercise group much better or very much better compared with 27% of the flexibility training group; a 136-person trial found exercise associated with significant improvements in fatigue and functional work capacity. CBT trials: in 60 people, 73% receiving CBT improved compared with 27% receiving standard care; in another 60 people, 63% had a good outcome with CBT compared with 17% with relaxation therapy. An IgG trial randomised 49 patients; ten of 23 immunoglobulin recipients improved compared with three of 26 placebo recipients. An NADH crossover trial had 33 completers and 26 analysed; 8/26 attained a 10% improvement compared with 2/26 on placebo. Harms included up to 15% withdrawing from active antidepressant treatment because of adverse drug effects, and IgG adverse effects in up to 82% of trial participants.